Key facts
- Notable investors include Mashup Ventures.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Arslon
- ·The full record, as it builds
Funding rounds
No funding rounds for Arslon are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Arslon
Developer of artificial intelligence-based medical software designed to diagnose coronary artery disease early in patients. The company's platform offers electrocardiogram data to noninvasively analyze a patient's condition and assist medical professionals in making diagnoses, and the software comparative analysis of the benefits and risks of drug therapy and invasive treatments, enabling healthcare institutions to diagnose the disease and provide treatment recommendations.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2025
- Website
- arslon.kr/
- Ownership
- Privately Held (backing)
Arslon doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Arslon shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Arslon in its N-PORT filings yet. We sweep new filings monthly.